Deregulation of PDGF-BB/PDGFR signaling is implicated in driving EMT, CSC self-renewal, metastatic potential, and chemoresistance in several cancers, including UCB, via activation of the PI3K and MAPK signaling pathways [82,83,84,85,86,87,88]. Here, PDGFRB is linked to cancer.